N-Acetylcysteine Prevents Loss of Dopaminergic Neurons in the EAAC1(-/-) Mouse

Department of Neurology, University of California, San Francisco, San Francisco Veterans Affairs Medical Center, USA.
Annals of Neurology (Impact Factor: 11.91). 03/2011; 69(3):509-20. DOI: 10.1002/ana.22162
Source: PubMed

ABSTRACT Dopaminergic neuronal death in Parkinson's disease (PD) is accompanied by oxidative stress and preceded by glutathione depletion. The development of disease-modifying therapies for PD has been hindered by a paucity of animal models that mimic these features and demonstrate an age-related progression. The EAAC1(-/-) mouse may be useful in this regard, because EAAC1(-/-) mouse neurons have impaired neuronal cysteine uptake, resulting in reduced neuronal glutathione content and chronic oxidative stress. Here we aimed to (1) characterize the age-related changes in nigral dopaminergic neurons in the EAAC1(-/-) mouse, and (2) use the EAAC1(-/-) mouse to evaluate N-acetylcysteine, a membrane-permeable cysteine pro-drug, as a potential disease-modifying intervention for PD.
Wild-type mice, EAAC1(-/-) mice, and EAAC1(-/-) mice chronically treated with N-acetylcysteine were evaluated at serial time points for evidence of oxidative stress, dopaminergic cell death, and motor abnormalities.
EAAC1(-/-) mice showed age-dependent loss of dopaminergic neurons in the substantia nigra pars compacta, with more than 40% of these neurons lost by age 12 months. This neuronal loss was accompanied by increased nitrotyrosine formation, nitrosylated α-synuclein, and microglial activation. These changes were substantially reduced in mice that received N-acetylcysteine.
These findings suggest that the EAAC1(-/-) mouse may be a useful model of the chronic neuronal oxidative stress that occurs in PD. The salutary effects of N-acetylcysteine in this mouse model provide an impetus for clinical evaluation of glutathione repletion in PD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Three glutamate transporters, GLT-1, GLAST, and EAAC1, are expressed in striatum. GLT-1 and, to a lesser extent, GLAST are thought to play a primary role in glutamate reuptake and mitigate excitoxicity. Progressive tyrosine hydroxylase (TH) loss seen in Parkinson's disease (PD) is associated with increased extracellular glutamate. Glutamate receptor antagonists reduce nigrostriatal loss in PD models. These observations suggest that excess synaptic glutamate contributes to nigrostriatal neuron loss seen in PD. Decreased GLT-1 expression occurs in neurodegenerative disease and PD models, suggesting decreased GLT-1-mediated glutamate reuptake contributes to excitotoxicity. To determine how transient GLT-1 blockade affects glutamate reuptake dynamics and a Ca(2+)-dependent process in nigrostriatal terminals, ser(19) phosphorylation of TH, the GLT-1 inhibitor dihydrokainic acid (DHK) was delivered unilaterally to striatum in vivo and glutamate reuptake was quantified ex vivo in crude synaptosomes 3h later. Ca(2+)-influx is associated with excitotoxic conditions. The phosphorylation of TH at ser(19) is Ca(2+)-dependent, and a change resulting from GLT-1 blockade may signify the potential for excitotoxicity to nigrostriatal neurons. Synaptosomes from DHK infused striatum had a 43% increase in glutamate reuptake in conjunction with decreased ser(19) TH phosphorylation. Using a novel GLAST inhibitor and DHK, we determined that the GLAST-mediated component of increased glutamate reuptake increased 3-fold with no change in GLAST or GLT-1 protein expression. However, GLT-1 blockade increased EAAC1 protein expression ~20%. Taken together, these results suggest that GLT-1 blockade produces a transient increase in GLAST-mediated reuptake and EAAC1 expression coupled with reduced ser(19) TH phosphorylation. These responses could represent an endogenous defense against excitotoxicity to the nigrostriatal pathway.
    Experimental Neurology 01/2012; 234(2):428-36. DOI:10.1016/j.expneurol.2012.01.012 · 4.62 Impact Factor
  • Source
    Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring, 12/2011; , ISBN: 978-953-307-485-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabonomics aims to measure the global, dynamic metabolic response of living system to biological stimuli. This approach requires to get a fingerprint analysis of body fluids (urine, plasma, etc.) using various spectroscopic methods, like 1H-NMR or mass spectrometry. Therefore, statistical datamining of spectra is necessary to extract the useful metabolic information. Metabonomics, by monitoring all influencing factors without making any assumption about their respective involvement, can detect properties about new toxicants and some putative related mechanisms of so-induced disruptive events. Metabonomics was used to investigate the toxicity of a plant, Hypochoeris radicata (HR), involved in a neurological horse disease, called Australian stringhalt. First described in 1848, this peripheral neuropathy induced by this plant, only observed in horse, leads to abnormal characteristic movements of hindlimbs and a laryngeal paresis. This affection was chosen as a toxicological model to apply metabonomics on a complex matrix to reveal unknown toxic principles without having any pathophysiological information. Without clinical trouble observed, the urinary fingerprinting of HR-treated mice allowed to reveal the main involved metabolite, scyllo-inositol, which is also found as a biomarker in liver and brain. In order to know whether scyllo-inositol is really a HR intoxication marker, brains of HR-treated mice were analyzed by magnetic resonance imaging, and confirmed the presence of abnormal concentrations of scyllo-inositol. Besides, we carried out behavioural tests demonstrating the HR infraclinical impact. Metabonomics provides a powerful approach to explore retrospectively the markers of a disease risk and to provide some indications of a pathophysiological situation. Several doses of the xenobiotics have to be tested to improve chemometric analysis of biological NMR spectra. Interestingly, this technology is being developed in the pharmaceutical industry for drug screening and for new candidate medicine selection. If genetic and individual effects on the metabolic status can be attenuated in laboratory animals, the challenge is from now on detection of subtle disruptions within the huge adaptable and complex biochemical system of the sick horses.
    16th North American Regional International society for the study of xenobiotics Meeting;